Project Details
Description
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolera Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosi
| Status | Active |
|---|---|
| Effective start/end date | 4/1/22 → 3/31/27 |
Funding
- RIVER 3 RENAL CORP
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.